Diagnósticos da América S.A (DASA3) - Net Assets
Based on the latest financial reports, Diagnósticos da América S.A (DASA3) has net assets worth R$7.84 Billion BRL (≈ $1.54 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$21.10 Billion ≈ $4.14 Billion USD) and total liabilities (R$13.26 Billion ≈ $2.60 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check DASA3 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$7.84 Billion |
| % of Total Assets | 37.17% |
| Annual Growth Rate | 20.12% |
| 5-Year Change | 124.39% |
| 10-Year Change | 184.44% |
| Growth Volatility | 66.31 |
Diagnósticos da América S.A - Net Assets Trend (2000–2024)
This chart illustrates how Diagnósticos da América S.A's net assets have evolved over time, based on quarterly financial data. Also explore DASA3 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Diagnósticos da América S.A (2000–2024)
The table below shows the annual net assets of Diagnósticos da América S.A from 2000 to 2024. For live valuation and market cap data, see market value of Diagnósticos da América S.A.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | R$7.94 Billion ≈ $1.56 Billion |
+8.21% |
| 2023-12-31 | R$7.33 Billion ≈ $1.44 Billion |
+3.45% |
| 2022-12-31 | R$7.09 Billion ≈ $1.39 Billion |
-6.08% |
| 2021-12-31 | R$7.55 Billion ≈ $1.48 Billion |
+113.44% |
| 2020-12-31 | R$3.54 Billion ≈ $693.93 Million |
+8.37% |
| 2019-12-31 | R$3.26 Billion ≈ $640.33 Million |
-1.75% |
| 2018-12-31 | R$3.32 Billion ≈ $651.72 Million |
+0.04% |
| 2017-12-31 | R$3.32 Billion ≈ $651.43 Million |
+16.04% |
| 2016-12-31 | R$2.86 Billion ≈ $561.39 Million |
+2.55% |
| 2015-12-31 | R$2.79 Billion ≈ $547.44 Million |
+0.64% |
| 2014-12-31 | R$2.77 Billion ≈ $543.95 Million |
+2.34% |
| 2013-12-31 | R$2.71 Billion ≈ $531.52 Million |
+3.90% |
| 2012-12-31 | R$2.61 Billion ≈ $511.58 Million |
+2.56% |
| 2011-12-31 | R$2.54 Billion ≈ $498.79 Million |
+313.41% |
| 2010-12-31 | R$614.89 Million ≈ $120.65 Million |
+11.06% |
| 2009-12-31 | R$553.64 Million ≈ $108.63 Million |
+15.22% |
| 2008-12-31 | R$480.51 Million ≈ $94.29 Million |
-6.34% |
| 2007-12-31 | R$513.07 Million ≈ $100.67 Million |
+9.35% |
| 2006-12-31 | R$469.21 Million ≈ $92.07 Million |
+76.17% |
| 2005-12-31 | R$266.33 Million ≈ $52.26 Million |
+9.03% |
| 2004-12-31 | R$244.26 Million ≈ $47.93 Million |
+81.49% |
| 2003-12-31 | R$134.59 Million ≈ $26.41 Million |
+12.40% |
| 2002-12-31 | R$119.74 Million ≈ $23.50 Million |
-8.83% |
| 2001-12-31 | R$131.34 Million ≈ $25.77 Million |
+34.64% |
| 2000-12-31 | R$97.55 Million ≈ $19.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Diagnósticos da América S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 287876900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | R$19.54 Billion | 246.52% |
| Other Comprehensive Income | R$-8.66 Billion | -109.20% |
| Total Equity | R$7.93 Billion | 100.00% |
Diagnósticos da América S.A Competitors by Market Cap
The table below lists competitors of Diagnósticos da América S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Metals Acquisition Limited
NYSE:MTAL
|
$829.10 Million |
|
Camden National Corporation
NASDAQ:CAC
|
$829.12 Million |
|
ADTRAN Inc
NASDAQ:ADTN
|
$829.20 Million |
|
J Resources Asia Pasifik Tbk
JK:PSAB
|
$829.49 Million |
|
BlackRock Technology and Private Equity Term Trust
NYSE:BTX
|
$828.64 Million |
|
Theravance Biopharma Inc
F:0TB
|
$828.57 Million |
|
Standard Foods Corp
TW:1227
|
$828.56 Million |
|
Heritage Commerce Corp
NASDAQ:HTBK
|
$828.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Diagnósticos da América S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,330,427,000 to 7,926,007,000, a change of 595,580,000 (8.1%).
- Net loss of 1,198,990,000 reduced equity.
- Dividend payments of 10,083,000 reduced retained earnings.
- New share issuances of 1,592,857,000 increased equity.
- Other comprehensive income increased equity by 199,591,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$-1.20 Billion | -15.13% |
| Dividends Paid | R$10.08 Million | -0.13% |
| Share Issuances | R$1.59 Billion | +20.1% |
| Other Comprehensive Income | R$199.59 Million | +2.52% |
| Other Changes | R$12.21 Million | +0.15% |
| Total Change | R$- | 8.12% |
Book Value vs Market Value Analysis
This analysis compares Diagnósticos da América S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.53x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.97x to 0.53x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | R$1.14 | R$3.38 | x |
| 2005-12-31 | R$1.24 | R$3.38 | x |
| 2006-12-31 | R$2.04 | R$3.38 | x |
| 2007-12-31 | R$2.23 | R$3.38 | x |
| 2008-12-31 | R$2.09 | R$3.38 | x |
| 2009-12-31 | R$2.35 | R$3.38 | x |
| 2010-12-31 | R$2.68 | R$3.38 | x |
| 2011-12-31 | R$8.18 | R$3.38 | x |
| 2012-12-31 | R$8.34 | R$3.38 | x |
| 2013-12-31 | R$8.71 | R$3.38 | x |
| 2014-12-31 | R$8.91 | R$3.38 | x |
| 2015-12-31 | R$8.97 | R$3.38 | x |
| 2016-12-31 | R$8.65 | R$3.38 | x |
| 2017-12-31 | R$10.05 | R$3.38 | x |
| 2018-12-31 | R$10.06 | R$3.38 | x |
| 2019-12-31 | R$9.77 | R$3.38 | x |
| 2020-12-31 | R$7.36 | R$3.38 | x |
| 2021-12-31 | R$13.46 | R$3.38 | x |
| 2022-12-31 | R$12.68 | R$3.38 | x |
| 2023-12-31 | R$9.81 | R$3.38 | x |
| 2024-12-31 | R$6.34 | R$3.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Diagnósticos da América S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.83%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 3.34x
- Recent ROE (-15.13%) is below the historical average (1.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -7.72% | -4.21% | 0.84x | 2.18x | R$-43.29 Million |
| 2005 | 3.82% | 1.92% | 0.90x | 2.20x | R$-16.44 Million |
| 2006 | 3.52% | 2.46% | 0.66x | 2.17x | R$-30.41 Million |
| 2007 | 11.05% | 6.59% | 0.70x | 2.38x | R$5.38 Million |
| 2008 | -2.52% | -1.06% | 0.61x | 3.86x | R$-59.94 Million |
| 2009 | 18.44% | 7.16% | 0.84x | 3.07x | R$45.49 Million |
| 2010 | 15.93% | 6.52% | 0.77x | 3.16x | R$36.48 Million |
| 2011 | 5.72% | 6.67% | 0.51x | 1.68x | R$-108.78 Million |
| 2012 | 3.27% | 3.76% | 0.53x | 1.64x | R$-175.49 Million |
| 2013 | 4.85% | 5.36% | 0.52x | 1.73x | R$-139.52 Million |
| 2014 | 2.97% | 3.05% | 0.59x | 1.66x | R$-194.84 Million |
| 2015 | 0.85% | 0.85% | 0.60x | 1.68x | R$-255.09 Million |
| 2016 | 3.31% | 3.12% | 0.59x | 1.81x | R$-191.27 Million |
| 2017 | 3.94% | 3.87% | 0.54x | 1.87x | R$-202.10 Million |
| 2018 | 5.53% | 4.69% | 0.54x | 2.16x | R$-149.29 Million |
| 2019 | 3.81% | 2.86% | 0.49x | 2.70x | R$-202.45 Million |
| 2020 | -4.26% | -2.14% | 0.53x | 3.77x | R$-504.43 Million |
| 2021 | -3.00% | -2.17% | 0.45x | 3.08x | R$-980.80 Million |
| 2022 | -5.47% | -2.95% | 0.49x | 3.79x | R$-1.09 Billion |
| 2023 | -15.91% | -8.18% | 0.54x | 3.58x | R$-1.90 Billion |
| 2024 | -15.13% | -7.83% | 0.58x | 3.34x | R$-1.99 Billion |
Industry Comparison
This section compares Diagnósticos da América S.A's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,919,793,500
- Average return on equity (ROE) among peers: 5.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Diagnósticos da América S.A (DASA3) | R$7.84 Billion | -7.72% | 1.69x | $828.87 Million |
| Centro de Imagem Diagnósticos S.A (AALR3) | $743.32 Million | -0.56% | 0.97x | $88.77 Million |
| Fleury S.A. (FLRY3) | $5.10 Billion | 12.03% | 1.59x | $1.72 Billion |
About Diagnósticos da América S.A
Diagnósticos da América S.A., together with its subsidiaries, provides diagnostic and hospital services in Brazil and Argentina. It operates through Hospitals and Oncology; Diagnostics and Care Coordination; and International Diagnostics segments. The company offers outpatient doctors; medical and outpatient services; diagnostic support assistants for private patients or partner companies; care c… Read more